Ross Cummings

Associate

BSc (Hons), PhD, Fellow of the Chartered Institute of Patent Attorneys.

Ross studied medical microbiology at the University of Edinburgh and subsequently obtained a PhD in molecular biology and biochemistry at the London School of Hygiene and Tropical Medicine. His research involved studying cellular signalling and sexual development in the malaria parasite.

Ross joined Potter Clarkson in 2006 and specialises in the field of biotechnology, including recombinant technology, antibody therapies, drug screening assays and gene therapy technologies.

News & Publications

Date	News Infomation
Nov 23 2011	HGS v Eli Lilly: Bar for industrial applicability of gene patents in UK lowered and realigned with the EPO. On 2 November 2011, the UK Supreme Court (formerly the House of Lords) handed down its decision in Human Genome Sciences Inc (HGS) v Eli Lilly and Company (Lilly), which was primarily concerned with the issue of industrial applicability of claimed biological material. The judgment provides some welcome clarification of the level of disclosure required for industrial applicability in this field to be recognised. The full decision can be found at tiny.cc/neutrokine.

Date

News Infomation

Nov

2011

HGS v Eli Lilly: Bar for industrial applicability of gene patents in UK lowered and realigned with the EPO.

On 2 November 2011, the UK Supreme Court (formerly the House of Lords) handed down its decision in Human Genome Sciences Inc (HGS) v Eli Lilly and Company (Lilly), which was primarily concerned with the issue of industrial applicability of claimed biological material. The judgment provides some welcome clarification of the level of disclosure required for industrial applicability in this field to be recognised. The full decision can be found at tiny.cc/neutrokine.